• Small Molecules
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Who we are

We are an innovation-led contract research, development and manufacturing organization offering integrated scientific services from early discovery to commercial supply.

What we do

We offer clients a customized end-to-end solution to fulfil their R&D and manufacturing requirements. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations.

Discovery

Our Discovery Services span the entire spectrum of early stage research from target …

Development

Our Development Services encompass activities from pre-clinical to clinical trials…

Manufacturing

Our Manufacturing services include cGMP-compliant facilities for clinical supplies, registration batches…

Dedicated Centers

Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support…

InstaVisit - Visit Syngene Virtually

Syngene InstaVisit is an interactive virtual experience designed to give you a 360 degree view of Syngene’s world-class facilities and capabilities. The platform allows you to change your perspective, look around and zoom in as we take you on a guided tour of Syngene’s labs.

Visit Syngene virtually with a 360 degree view of Syngene’s world-class facilities and capabilities
0 +

Clients

0

Collaborations with the top 10 Pharma/Biotech companies

3000 +

Experienced Scientists

0

Mn sq. ft. of R&D and manufacturing infrastructure

0 +

Patents 

Seeing good demand for biologics manufacturing- Syngene CEO Jonathan Hunt

News
25th Oct, 2021

Syngene reports second quarter results Revenue from operations up 17% to Rs. 6,102 Mn, PAT increased 9% to Rs. 920 Mn

Press Release
20th Oct, 2021

Scientific breadth-depth of our portfolio contributing to developmentof new therapies- Mahesh Bhalgat

News
5th Oct, 2021

How Organocatalysis discovered by Nobel laureates revolutionised drug development and production in Syngene

Design of Experiment (DoE) – An efficient tool for process optimization

DoE is achieving increasing acceptance in the pharmaceutical sector as it is being seen as an efficient tool for process optimization, including helping to develop quality products.

Things you may not know about continuous flow chemistry

The continuous flow chemistry processes established in the lab can now be readily transferred to the production facilities and scaled up for commercial use without substantially altering reaction conditions.

Upcoming events

25th - 28th October, 2021
Virtual
25th to 29th October, 2021
Virtual
2nd to 4th November, 2021
Virtual

Corporate social responsibility

To strive towards developing and sustaining healthy and empowered communities by improving the quality of life.

Syngene International Ltd

+1.35(0.32%)+1.35(0.32%)

Governance

Behind consistent growth is good governance

Careers

Discover a world of opportunities

Annual Reports

Touching a billon lives through innnovation

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details